Navigation Links
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Date:1/5/2012

EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time.  The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:  Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 

 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
2. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
4. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
6. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
7. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
8. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
10. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
11. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/31/2017)... -- 7D Surgical, developer of ground breaking surgical navigation technologies, ... System to support its strategic sales plan in ... Virginia.  7D Surgical has entered into an exclusive sales representative ... facilities within those markets. ... Spartan Medical Purchases 7D ...
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “To Walk ... radioman on a B17 bomber named Edward Koontz. “To Walk Away” is the creation ... Scranton, who has published over two hundred manuscripts in chemistry and religion, as well ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... Los Angeles, California (PRWEB) , ... August 21, ... ... Physicians is announcing the addition of two plastic surgery fellows for academic year ... is designed for candidates who have successfully completed residency in Plastic and Reconstructive ...
(Date:8/21/2017)... Milwaukee, WI (PRWEB) , ... August 21, 2017 ... ... recent years, with events taking place all over the country. , Outdoor running ... that marathon runners are at an increased risk of melanoma, and only half ...
Breaking Medicine News(10 mins):